In 2018, Hong Kong Exchanges and Clearing overhauled rules that previously barred technology firms with so-called dual-class shares and “pre-revenue” biotechnology companies from listing in the city. Photo: Nora Tam In 2018, Hong Kong Exchanges and Clearing overhauled rules that previously barred technology firms with so-called dual-class shares and “pre-revenue” biotechnology companies from listing in the city. Photo: Nora Tam
In 2018, Hong Kong Exchanges and Clearing overhauled rules that previously barred technology firms with so-called dual-class shares and “pre-revenue” biotechnology companies from listing in the city. Photo: Nora Tam
SCMP Editorial
Opinion

Opinion

Editorial by SCMP Editorial

Vigilance is key as more mainland Chinese firms list in Hong Kong

  • Many companies, now unloved in the United States, are looking to city’s bourse to raise capital, meaning regulators must boost monitoring to ensure quality and protect investors

In 2018, Hong Kong Exchanges and Clearing overhauled rules that previously barred technology firms with so-called dual-class shares and “pre-revenue” biotechnology companies from listing in the city. Photo: Nora Tam In 2018, Hong Kong Exchanges and Clearing overhauled rules that previously barred technology firms with so-called dual-class shares and “pre-revenue” biotechnology companies from listing in the city. Photo: Nora Tam
In 2018, Hong Kong Exchanges and Clearing overhauled rules that previously barred technology firms with so-called dual-class shares and “pre-revenue” biotechnology companies from listing in the city. Photo: Nora Tam
READ FULL ARTICLE